- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06817122
Lo strumento "Let's Talk Tech" per supportare il processo decisionale sull'uso della tecnologia
Studio meccanicistico sull'intervento comportamentale diadico "Talking Tech" per supportare il processo decisionale sull'uso della tecnologia
The goal of this research is to educate people about different technologies to support care at home when someone is experiencing memory difficulties. "Let's Talk Tech" is a new tool to educate people about technologies commonly used to support care and monitor safety, and help families talk about their feelings about them to understand each other's perspectives. The goal of this clinical trial is to learn if "Let's Talk Tech" helps people feel more prepared to make decisions about technologies.
Researchers will compare Let's Talk Tech to usual care (no intervention) to see if Let's Talk Tech increases peoples' preparedness and confidence to make decisions about technologies.
All participants will:
- Use the Let's Talk Tech web application together with their study partner that takes up to an hour or do nothing.
- Complete two surveys. The second survey will be taken within 2 weeks of the first.
One participant in each pair will also take a 3rd short survey 3 months after the first.
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
The goal of this research is to help families understand digital health technology options to support dementia care at home so they can negotiate immediate decisions and future use in an informed way. This is a mechanism-focused trial of Let's Talk Tech (LTT), a single-use, self-administered intervention in the form of a web application. It targets education and interpersonal communication processes to enable informed decision making and planning for technology use that relieves care partners of the burden of making decisions without awareness of the person's preferences. Participants are people living with mild Alzheimer's disease (AD) and AD-related dementias (PLWD) or mild cognitive impairment (MCI) and a care partner. The 120 enrolled dyads (60 per study group) will be randomly assigned to receive either the intervention or usual care control. The intervention is self-administered. All participants will complete measures at baseline and at post-test (2 weeks), and care partners will also complete them 3 months later. Aim 1 will test if LTT compared with usual care improves the hypothesized mechanisms of change that are care partners' technology awareness, understanding, communication satisfaction, and intention to honor the PLWD/MCI's preferences, as well as both care partner- and PLWD/MCI-reported dyadic alignment. Aim 2 will examine if and how those hypothesized mechanisms of change improve the post-test and 3-month primary outcomes of care partner preparedness, decisional conflict, and decision making confidence, and secondary outcomes of PLWD/MCI and care partner sharing of technology preferences beyond the dyad and their confidence that PLWD/MCI's preferences will be honored. Exploratory Aim 3 will examine how, with whom, and for what purpose dyad members share technology preferences and explore factors that vary for those who shared with providers vs. family/friends, with the hope of learning how to expand the reach of this intervention to activate dyads' entire care networks.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98105
- University of Washington
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria for Patients:
- have mild cognitive impairment (MCI) or mild dementia
- age 55 or older
- able to understand and speak English
Inclusion Criteria for Co-participants:
- be identified by the patient as their primary support person
- age 18 or older
- able to understand and speak English
- able to complete LTT together with their study partner at the same time
Exclusion Criteria:
- None
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Let's Talk Tech intervention
The intervention group will complete the single use self-administered Let's Talk Tech intervention together as a dyad. |
Let's Talk Tech is a self-administered dyadic education and communication tool delivered as a web application to support shared decision making about technology use. |
|
Nessun intervento: Usual care
This control group will receive usual care, which means they will complete no intervention. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Preparedness to make technology decisions
Lasso di tempo: baseline, 2-week post-test and 3 months
|
This is one of the three primary outcomes that are not mechanisms of change variables. Participant rates on a 5-point Likert scale [1="Strongly agree" to 5="Strongly disagree"] how much they agree with the statement that they feel prepared to make decisions about technology use for their study partner. |
baseline, 2-week post-test and 3 months
|
|
Decisional Conflict Scale
Lasso di tempo: baseline, 2-week post-test and 3 months
|
This is one of the three primary outcomes that are not mechanisms of change variables. The Decisional Conflict Scale is a 16-item scale with 5 response categories [0= "Strongly agree" to 4="Strongly disagree"]. Higher scores reflect higher decisional conflict in decision making. |
baseline, 2-week post-test and 3 months
|
|
Decision Making Confidence Scale (adapted)
Lasso di tempo: baseline, 2-week post-test and 3 months
|
This is one of the three primary outcomes that are not mechanisms of change variables. This is a six-item scale with 5 response categories [0="Not confident at all" to 4= "Very confident"]. Higher scores reflect higher confidence in decision making. |
baseline, 2-week post-test and 3 months
|
|
Technology awareness
Lasso di tempo: baseline and 2-week post-test
|
Participant rates on a 5-point Likert scale [1="Very aware" to 5="Very unaware"] how aware they are about technologies available to support their partner's care and safety. |
baseline and 2-week post-test
|
|
Technology understanding
Lasso di tempo: baseline and 2-week post-test
|
4 items assess perceived understanding of each of 4 technologies featured in the intervention [1="Not at all" to 5="Completely"]. |
baseline and 2-week post-test
|
|
Perception of PLWD/MCI's technology understanding
Lasso di tempo: baseline and 2-week post-test
|
4 items assess care partner's perception of how well their study partner understands of each of 4 technologies featured in the intervention [1="Not at all" to 5="Completely"]. |
baseline and 2-week post-test
|
|
Satisfaction with dyadic communication about technology
Lasso di tempo: baseline and 2-week post-test
|
Participant rates on a 5-point Likert scale [1="Very satisfied" to 5="Very dissatisfied"] how satisfied they are with their discussion with their study partner about using technology to support their care or safety. |
baseline and 2-week post-test
|
|
Intention to honor preferences
Lasso di tempo: baseline and 2-week post-test
|
Participant rates on a 5-point Likert scale [1="Very likely" to 5="Very unlikely"] how likely they are to honor their partner's preferences for how technology is used in their care. |
baseline and 2-week post-test
|
|
Dyadic alignment about technology use
Lasso di tempo: baseline and 2-week post-test
|
Participant is asked how much they agree with their partner about using technologies to support their care [1="Not at all" to 5="Completely"]. |
baseline and 2-week post-test
|
|
Had conversation about technology
Lasso di tempo: baseline and 2-week post-test
|
Participant answers yes, no or unsure if they've ever had a conversation with their study partner about technology to support care or safety. |
baseline and 2-week post-test
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Shared technology preferences
Lasso di tempo: baseline, 2-week post-test and 3 months
|
Participant answer yes or no if they have ever shared the PLWD/MCI's preferences about technologies to support their care with anyone else. |
baseline, 2-week post-test and 3 months
|
|
Confidence preferences will be honored
Lasso di tempo: baseline, 2-week post-test and 3 months
|
Participant rates on a 5-point Likert scale [1=Strongly agree to 5=Strongly disagree] about their belief the PLWD/MCI's choices about these technologies will be honored. |
baseline, 2-week post-test and 3 months
|
|
Satisfaction with involvement of primary participant in technology use decisions
Lasso di tempo: baseline, 2-week post-test and 3 months
|
Participant rates on a 5-point Likert scale [1="Very satisfied" to 5="Very dissatisfied"] how satisfied they are with how involved the primary participant is in decisions about technology to support their care. |
baseline, 2-week post-test and 3 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Clara Berridge, PhD, University of Washington
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Disordini mentali
- Neoplasie
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Disturbi neurocognitivi
- Disturbi cognitivi
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Linfoma non Hodgkin
- Linfoma
- Malattie emiche e linfatiche
- Disfunzione cognitiva
- Linfoma, follicolare
- Demenza
Altri numeri di identificazione dello studio
- STUDY00020570
- 1P30AG086562-01 (Sovvenzione/contratto NIH degli Stati Uniti)
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .